← Companies|Bio-Manguinhos
Bi

Bio-Manguinhos

Rio de Janeiro BRFounded 19762,000 employees
Private CapgovPrivateInfectious Disease
Platform: Fiocruz Vaccines
Market Cap
N/A
All Drugs
5
Clinical Trials
5
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (5 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
BIO-IIT-877BIO-IIT-877Preclinical1mAbAHRCDK4/6iSCLC
BIO-IIT-937BIO-IIT-937Preclinical1MultispecificAuroraAALKiMyelofibrosis
BIO-IIT-463BIO-IIT-463Approved1Gene EditingNectin-4CGRPantHeart Failure
BIO-IIT-514BIO-IIT-514Phase 1/21DegraderFcRnBiTESMA
BIO-IIT-157BIO-IIT-157Phase 11siRNAVEGFCAR-T CD19NB
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (5)
2025-04-17
BIO-IIT-937 Interim
Myelofibrosis
Past
2026-08-10
BIO-IIT-937 Orphan Drug
Myelofibrosis
Orphan Drug
2027-12-27
BIO-IIT-157 Interim
NB
Interim
2029-11-18
BIO-IIT-877 Interim
SCLC
Interim
2030-02-09
BIO-IIT-514 Ph2 Data
SMA
Ph2 Data